RP-832c
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


RP-832c
Description:
RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM) . RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) [1][2].UNSPSC:
12352209Target:
Apoptosis; TNF ReceptorRelated Pathways:
ApoptosisApplications:
COVID-19-immunoregulationField of Research:
Cancer; Inflammation/ImmunologyPurity:
98.16Solubility:
DMSO : 25 mg/mL (ultrasonic)Smiles:
O=C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=CC=C3)C(NCC(NCC(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)NMolecular Formula:
C68H94N20O11Molecular Weight:
1367.60References & Citations:
[1]Carla Portocarrero, et al; Targeting Immunosuppressive Macrophages in the Cutaneous T-Cell Lymphoma Microenvironment. Blood 2022; 140 (Supplement 1) : 3146–3147.|[2]Ghebremedhin A, et al. A Novel CD206 Targeting Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice. Cells. 2023 Apr 26;12 (9) :1254.Shipping Conditions:
Blue IceStorage Conditions:
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)Scientific Category:
PeptidesClinical Information:
No Development ReportedCAS Number:
[2375823-45-1]
